Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Is HIV a provoking factor for venous thrombotic events?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. How do we preserve health among adults living with HIV?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Language used to convey HIV infection risk is important - Authors' reply

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  1. Compassionate Use of Remdesivir in Covid-19

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Interstitial lung abnormalities in people with HIV infection and uninfected controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Andrew N Phillips
  • Francois Venter
  • Diane Havlir
  • Anton Pozniak
  • Daniel Kuritzkes
  • Annemarie Wensing
  • Jens D Lundgren
  • Andrea De Luca
  • Deenan Pillay
  • John Mellors
  • Valentina Cambiano
  • Loveleen Bansi-Matharu
  • Fumiyo Nakagawa
  • Thokozani Kalua
  • Andreas Jahn
  • Tsitsi Apollo
  • Owen Mugurungi
  • Polly Clayden
  • Ravindra K Gupta
  • Ruanne Barnabas
  • Paul Revill
  • Jennifer Cohn
  • Silvia Bertagnolio
  • Alexandra Calmy
Vis graf over relationer

BACKGROUND: The integrase inhibitor dolutegravir could have a major role in future antiretroviral therapy (ART) regimens in sub-Saharan Africa because of its high potency and barrier to resistance, good tolerability, and low cost, but there is uncertainty over appropriate policies for use relating to the potential for drug resistance spread and a possible increased risk of neural tube defects in infants if used in women at the time of conception. We used an existing individual-based model of HIV transmission, progression, and the effect of ART with the aim of informing policy makers on approaches to the use of dolutegravir that are likely to lead to the highest population health gains.

METHODS: We used an existing individual-based model of HIV transmission and progression in adults, which takes into account the effects of drug resistance and differential drug potency in determining viral suppression and clinical outcomes to compare predicted outcomes of alternative ART regimen policies. We calculated disability adjusted life-years (DALYs) for each policy, assuming that a woman having a child with a neural tube defect incurs an extra DALY per year for the remainder of the time horizon and accounting for mother-to-child transmission. We used a 20 year time horizon, a 3% discount rate, and a cost-effectiveness threshold of US$500 per DALY averted.

FINDINGS: The greatest number of DALYs is predicted to be averted with use of a policy in which tenofovir, lamivudine, and dolutegravir is used in all people on ART, including switching to tenofovir, lamivudine, and dolutegravir in those currently on ART, regardless of current viral load suppression and intention to have (more) children. This result was consistent in several sensitivity analyses. We predict that this policy would be cost-saving.

INTERPRETATION: Using a standard DALY framework to compare health outcomes from a public health perspective, the benefits of transition to tenofovir, lamivudine, and dolutegravir for all substantially outweighed the risks.

FUNDING: Bill & Melinda Gates Foundation.

OriginalsprogEngelsk
TidsskriftThe Lancet HIV
Vol/bind6
Udgave nummer2
Sider (fra-til)e116-e127
ISSN2352-3018
DOI
StatusUdgivet - 2019

ID: 55821645